What Is Retatrutide?

Retatrutide is a single-molecule peptide that activates three distinct metabolic hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. While GLP-1 agonists like Semaglutide and dual GLP-1/GIP agonists like Tirzepatide have already transformed weight loss treatment, Retatrutide's addition of glucagon receptor activity introduces a mechanism that directly increases energy expenditure and hepatic fat oxidation — addressing obesity from both the intake and expenditure sides of the energy equation.

Phase II trial results published in the New England Journal of Medicine showed Retatrutide producing the largest weight reductions ever recorded in an obesity drug trial, positioning it as potentially the most effective pharmacological weight loss agent ever developed. Eli Lilly is currently conducting Phase III trials with results expected in 2026.

Retatrutide's triple-agonist mechanism creates a synergistic metabolic effect:

• GLP-1 receptor agonism — Reduces appetite by acting on hypothalamic hunger centers, slows gastric emptying to increase satiety, and enhances glucose-dependent insulin secretion.
• GIP receptor agonism — Complements GLP-1 effects on insulin secretion and may enhance fat tissue sensitivity to lipid mobilization signals. GIP co-agonism also appears to improve tolerability of GLP-1 effects.
• Glucagon receptor agonism — The key differentiator. Glucagon activation increases hepatic glucose output, stimulates fat oxidation in the liver, increases energy expenditure (thermogenesis), and promotes the mobilization of stored fat — particularly hepatic and visceral fat.
• Synergistic energy balance — While GLP-1 reduces energy intake, glucagon increases energy expenditure. This dual approach creates a larger caloric deficit than either mechanism alone.

The challenge of adding glucagon agonism is that glucagon raises blood sugar — but the concurrent GLP-1 and GIP agonism counterbalances this effect by enhancing insulin secretion, resulting in net glycemic improvement.

Phase II clinical trial results for Retatrutide are remarkable:

• Up to 24.2% body weight loss — The highest dose group (12 mg) achieved a mean 24.2% weight reduction over 48 weeks, surpassing all existing obesity medications.
• Near-complete liver fat resolution — In a sub-study, 90% of participants with fatty liver disease achieved complete resolution of hepatic steatosis.
• Significant metabolic improvements — Reductions in HbA1c, fasting glucose, triglycerides, and blood pressure were observed across dose groups.
• Waist circumference reduction — Substantial reductions in waist circumference reflect preferential visceral fat loss.
• Dose-dependent response — Clear dose-response relationship suggests further optimization may be possible.

Retatrutide is administered via once-weekly subcutaneous injection with a dose-escalation protocol:

• Starting dose — Clinical trials began at 0.5 mg weekly for the first 4 weeks to establish tolerability.
• Escalation — Doses were titrated upward every 4 weeks, progressing through 1 mg, 2 mg, 4 mg, 8 mg, to the maximum studied dose of 12 mg.
• Maintenance dose — 8–12 mg once weekly produced the most significant weight loss results in Phase II trials.
• Injection site — Subcutaneous injection in the abdomen, thigh, or upper arm.

The slow dose escalation is critical for managing gastrointestinal side effects. Retatrutide should be stored refrigerated and protected from light. As an investigational compound, commercial formulations are not yet available.

Retatrutide's side effect profile is consistent with other incretin-based therapies, though the glucagon component adds unique considerations:

• Gastrointestinal effects — Nausea (most common), diarrhea, vomiting, and decreased appetite were reported, primarily during dose escalation. These generally attenuated over time.
• Heart rate increase — Small increases in resting heart rate (2–4 bpm) were observed, consistent with GLP-1 agonist class effects.
• Injection site reactions — Mild erythema and discomfort at injection sites reported in some participants.
• Hypoglycemia — Rare, primarily in participants also taking sulfonylureas or insulin.

The addition of glucagon agonism did not appear to worsen glycemic control in trials, as the GLP-1/GIP components adequately counterbalanced glucagon's hyperglycemic effects.

Retatrutide is an investigational drug currently in Phase III clinical trials. It is not approved for any use by the FDA or any regulatory agency. Research peptide versions are sold strictly for in vitro research purposes only. This article is for informational purposes and does not constitute medical advice.

As an investigational compound, Retatrutide availability is limited to research peptide vendors. Quality considerations are especially important:

• Structural complexity — Retatrutide is a large, complex peptide. Only vendors with sophisticated synthesis capabilities can produce it reliably.
• Rigorous testing required — Demand COAs with HPLC purity ≥98% and mass spectrometry confirming the correct molecular weight.
• Cold chain essential — Proper storage and shipping are critical for maintaining peptide integrity.

Ascension Peptides is our recommended source for research-grade Retatrutide. They provide 99%+ purity with comprehensive COAs from independent laboratories, US-based shipping with cold chain handling, and the quality control infrastructure needed for complex peptides like Retatrutide. Their responsive support team can address technical questions about handling and storage.